Tandem transplantation in lymphoma

Bone Marrow Transplant. 2001 Sep;28(6):529-35. doi: 10.1038/sj.bmt.1703201.

Abstract

The majority of poor-risk lymphoma patients are not cured with conventional chemotherapy. There is evidence for the superiority of single high-dose chemotherapy in such patients, but many still die from recurrent disease. Strategies to improve survival in these poor-risk patients include dose-intensification with high-dose chemotherapy and PBPC support, tandem autologous HDC with PBPC support, and autologous followed by non-myeloablative allogeneic transplantation. These more aggressive strategies are feasible and tolerable. Whether tandem transplantation will prove more effective than current single high-dose therapy in appropriately selected patients remains to be determined.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Combined Modality Therapy / methods
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Lymphoma / drug therapy
  • Lymphoma / mortality
  • Lymphoma / therapy*
  • Salvage Therapy / methods*
  • Transplantation, Autologous